SecBot SecBot
SECBOTREPLAY Home › Report › KPTI

KPTI · Six KPTI insiders, including the CEO and other C-suite executives, sold…

Karyopharm Therapeutics Inc. · CLUSTER filed May 15, 2026 at 16:08 ET

At the news

NEUTRALIMPACT 3/10

CLUSTER filed May 15, 2026 at 16:08 ET

Six KPTI insiders, including the CEO and other C-suite executives, sold a total of $35K in shares on May 14, 2026, the same day as the Q1 earnings release. The sales are minimal in size (0.019% of market cap) and likely routine post-earnings transactions. Three directors received non-cash stock grants on May 21. The sales do not signal bearish sentiment given their trivial value, but the company faces significant going-concern risk and potential dilution from a $400M shelf registration.

  • Six C-suite insiders sold a total of $35K in shares on May 14, 2026, all at $9.50/share.
  • Three directors received grants of 15,508 shares each on May 21, 2026, at $0 (non-cash).
  • Total insider sales represent 0.019% of KPTI's $185M market cap, well below materiality threshold.
  • Q1 2026 revenue was $35.1M (up 17% YoY), net loss $22.4M, beat consensus EPS of -$1.44 by 29%.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access